P-170糖蛋白、GST-π、TOPOⅡ及PCNA在非小细胞肺癌中的表达及意义  

THE SIGNIFICANCE OF P-170 GLUCOPROTEIN,GST-π,TOPO Ⅱ AND PCNA EXPRESSION IN NON-SMALL CELL LUNG CARCINOMA

作　　者：王小斌[1] 王轶楠[1] 李红民[1] 冯庆庚[2] 杨淑慧[1] 张凤英[2] 

机构地区：[1]河北省唐山市肿瘤医院 [2]唐山市卫校附属医院,063000

出　　处：《中国煤炭工业医学杂志》1999年第6期622-624,共3页Chinese Journal of Coal Industry Medicine

摘　　要：目的　探讨耐药因子:P-170糖蛋白、谷胱甘肽硫转移酶-π(GST-π)、拓扑异构酶(TOPO)以及增殖细胞核抗原(PC-NA)在非小细胞癌(NSCLC)中的表达及意义。方法　1990年1月～1996年12月取76例术前未经化疗,术后经病理证实的NSCLC患者的病理组织蜡块,用常规免疫组化SP法,检测P-170糖蛋白、GST-π、TOPO及PCNA的表达。结果　P-170糖蛋白的阳性率、GST-π高表达率、TOPO的阴性率、PCNA的高表达率分别为53.7%(41/76)、77.6%(59/76)、30.3%(23/76)、76.3%(58/76)。而且P-170糖蛋白与GST-π的表达呈正相关(rs=0.281,P<0.05)。P-170糖蛋白、GST-π分别与PCNA呈负相关趋势(rs=-0.265,0.05<P<0.10;rs=-0.259,0.05<P<0.10)。PCNA高表达组较低表达组生存率差异显著(P<0.05)。PCNA和GST-π两组均高表达较两组均低表达生存率亦有显著差异(P=0.045)。结论　P-170糖蛋白、GST-π、TOPO在NSCLC中的异常表达,与其原发性耐药有关。检测三种耐药因子及PCNA有助于临床上制定更合理的化疗方案和更加准确地估计预后。Objective To study the significance of P-170 glucoprotein,GST-π,TOPO Ⅱ and PCNA expression in non-small cell lung carcinoma.Methods 76 pathological tissue wax speciments not treated with chemical therapy before operation but phathologically proved to be NSCLS after operation,were examined by using immunohistochemical S-P method from January,1990 to December 1996.Results The positive rate of the P-170 glucoprotein, the high expression rate of GST-π,the negative rate of TOPO and the high expression rate of PCNA are respectively 53.7%(41/76),77.6%(59/76),30.3%(23/76),76.3%(58/76).The positive relevation is significant between the expression of the P-170 glucoprotein and GST-π(r\-s=0.281,P<0.05) The P-170 glucoprotein and GST-π is negatively related to PCNA respectively (r\-s=-0.265,0.05<P<0.10,r\-s=-0.259,0.05<P<0.10).There is sharp difference between the survival rates of PCNA high expression and PCNA low expression.(P<0.05),so are PCNA and GST-π(P=0.045).Conclusion:The unusual expressions of P-170 glucoprotein,GST-π,TOPO Ⅱ in NSCLS is related to the primary resistance of the acting of drugs. Detection of these three drug-resistance factors contributes to making more reasonable scheme of chemical therapy and predicting more correctly prognosis of NSCLC.

关 键 词：非小细胞肺癌 P-170糖蛋白 GST-Π TOPOⅡ 

分 类 号：R734.202[医药卫生—肿瘤]